文献速递物质与行为成瘾

酒精使用障碍与肥胖的交互作用:同一枚硬币的两面?

Crosstalk between alcohol use disorder and obesity: two sides of the same coin?
PubMed 文献 · Mol Psychiatry · 2025-09-27

本文为非系统性批判性综述,通过PubMed检索及递归参考文献追溯,梳理酒精使用障碍(AUD)与肥胖在神经生物学、病理生理、神经影像和临床特征上的重叠与交互。综述强调GLP-1疗法在减重与AUD治疗中的潜在双重作用,并讨论减重手术与饮酒变化的关系,认为研究二者重叠有助于发现新的治疗靶点。

要点

  • AUD与肥胖共享神经生物学及外周-脑机制,且均可导致肝病和心血管疾病等器官损害。
  • GLP-1疗法已获批用于减重,且 growing evidence 提示其对AUD及其他成瘾可能有效。
  • 减重手术后人群的饮酒变化值得关注,相关机制尚待进一步研究。

核心结论

  • 研究AUD与肥胖的重叠可揭示两种疾病发生与维持的机制,并可能为AUD及共病肥胖或代谢障碍识别新治疗靶点。

研究设计与样本

  • 非系统性批判性综述,通过PubMed检索、既有知识及递归参考文献追溯识别相关文献,并由图书馆员使用PubMed和Google Scholar补充检索。

主要发现

  • AUD与肥胖均为公共卫生问题,共享神经生物学和外周-脑机制,且常出现肝病和心血管疾病等相似的器官损害后果。
  • 有 growing evidence 显示接受减重手术治疗肥胖者饮酒行为发生变化。
  • 目前获批的肥胖药物与AUD药物存在部分重叠,GLP-1疗法因近期获批减重且 growing evidence 提示对AUD及其他成瘾可能有效而受到强调。

关键数值与推荐

  • 检索词包括alcohol、metabolic disorders、obesity、glucagon-like peptide-1(GLP-1)、bariatric surgery和gut-brain axis。

临床怎么用

  • 临床评估AUD或肥胖患者时应关注另一疾病及共同代谢并发症,并留意GLP-1疗法对两类疾病的潜在双重获益。
  • 对减重手术后患者应关注饮酒行为变化,并将其纳入随访评估。

局限性

  • 本文为非系统性批判性综述,非系统检索,可能存在选择偏倚,未提供定量合并结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Investigating similarities and differences between alcohol use disorder (AUD) and obesity is important because both AUD and obesity are public health concerns and share neurobiological and periphery-brain mechanisms. Furthermore, AUD and obesity often present with similar medical consequences related to organ damage, including liver and cardiovascular diseases. There is also growing evidence of changes in alcohol drinking in people who undergo bariatric surgery for obesity. In this non-systematic critical review, we identified relevant articles through PubMed searches, previous knowledge, and recursive reference searching. A librarian also used PubMed and Google Scholar for additional relevant articles, using terms such as alcohol, metabolic disorders, obesity, glucagon-like peptide-1 (GLP-1), bariatric surgery, and gut-brain axis. We provide an overview of the neurobiological, pathophysiological, neuroimaging, and clinical features related to the overlap and crosstalk between AUD and obesity. We also provide a summary of the currently approved medications for obesity and those for AUD and note the potential for some of these medications to work for both disorders. Specific to the latter point, we place emphasis on GLP-1 therapies, given their recent approval for weight loss and the growing evidence suggesting their potential efficacy for AUD and other addictions. We further review studies of the relationship between bariatric surgery and AUD and discuss potential mechanisms and future directions. In summary, studying the overlap between obesity and AUD may shed light on the mechanisms underlying the development and maintenance of both diseases. This knowledge, in turn, may help identify new therapeutic targets for AUD, and possibly comorbid obesity and/or other metabolic disorders.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Leggio L, Farokhnia M, Kenny PJ, et al. Crosstalk between alcohol use disorder and obesity: two sides of the same coin? Mol Psychiatry. 2025. PMID: 41015576. doi:10.1038/s41380-025-03259-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。